### Highlights of This Issue 1973

**SPECIAL FEATURES**

**CCR 20th Anniversary Commentary**
- **1975**
  - *CCR 20th Anniversary Commentary: Setting the Stage for Nanoparticle Albumin-Bound Paclitaxel—How Far Science Has Come*
    - Sami I. Bashour and Nuhad K. Ibrahim

**CCR Translations**
- **1978**
  - *PLEKH5: A Key to Unlock the Blood–Brain Barrier?*
    - Sylvia C. Eisele, Corey M. Gill, Ganesh M. Shankar, and Priscilla K. Brastianos
    - See related article, p. 2138

**CCR New Strategies**
- **1984**
  - New Strategies in Glioblastoma: Exploiting the New Biology
    - Howard A. Fine

**Molecular Pathways**
- **1989**
  - Molecular Pathways: Targeting NRG1 Fusions in Lung Cancer
    - Lynnette Fernandez-Cuesta and Roman K. Thomas

- **1995**
  - Molecular Pathways: A Novel Approach to Targeting Hypoxia and Improving Radiotherapy
    - Efficacy via Reduction in Oxygen Demand
    - Alexander Lin and Amit Maity

**Reviews**
- **2001**
  - Is This the Time to Introduce Minimal Residual Disease in Multiple Myeloma Clinical Practice?
    - Bruno Paiva, Noemi Puig, Ramón García-Sanz, and Jesús F. San Miguel on behalf of the Grupo Español de Mieloma (GEM)/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (PETHEMA) cooperative study groups

### 2009 Genomic Landscape of Human Papillomavirus–Associated Cancers
- Maria Rusan, Yvonne Y. Li, and Peter S. Hammerman

### CANCER THERAPY: CLINICAL

**2020**
- Impact of Chronic Graft-versus-Host Disease on Late Relapse and Survival on 7,489 Patients after Myeloablative Allogeneic Hematopoietic Cell Transplantation for Leukemia
  - See related commentary, p. 1981

### PERSONALIZED MEDICINE AND IMAGING

**2029**
- Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial
  - Lorraine A. Chantrill, Adnan M. Nagrial, Clare Watson, Amber L. Johns, Mona Martyn-Smith, Skye Simpson, Scott Mead, Marc D. Jones, Jaswinder S. Samra, Anthony J. Gill, Nicole Watson, Venessa T. Chin, Jeremy L. Humphris, Angela Chou, Belinda Brown, Adrienne Money, Marina Pajic, Sean M. Grimmmond, David K. Chang, David Thomas, Lucille Sebastian, Katrin Sjoquist, Sony Yip, Nick Pavlakis, Ray Aghari, Sandra Harvey, Peter Grimison, John Simes, and Andrew V. Blankin, on behalf of the Australian Pancreatic Cancer Genome Initiative (APGI) and the Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial Management Committee of the Australasian Gastrointestinal Trials Group (AGITG)

**2038**
- Polymorphisms in MIR27A Associated with Early-Onset Toxicity in Fluoropyrimidine-Based Chemotherapy
  - Ursula Amstutz, Steven M. Offer, Johanna Ststonen, Markus Joerger, Robert B. Diasio, and Carlo R. Lugard

**2045**
- Integrated Genomic Profiling, Therapy Response, and Survival in Adult Acute Myelogenous Leukemia
  - Brian Parkin, Peter Ouilllette, Mehmet Yildiz, Kamila Saiya-Cork, Kerby Shedden, and Sami N. Malek
### Table of Contents

**2167** IL2 Inducible T-cell Kinase, a Novel Therapeutic Target in Melanoma  

**2177** Identification of Biological Relevant Minor Histocompatibility Antigens within the B-lymphocyte–Derived HLA-Ligandome Using a Reverse Immunology Approach  
Pleun Hombrink, Chopie Hassan, Michel G.D. Kester, Lorenz Jahn, Margot J. Pont, Arnoud H. de Ru, Cornelis A.M. van Bergen, Marieke Griffioen, J.H. Frederik Falkenburg, Peter A. van Veelen, and Mirjam H.M. Heemskerk

**LETTERS TO THE EDITOR**

**2187** RAF plus EGFR Inhibition for BRAF-Mutant Metastatic Colorectal Cancer—Letter  
Steven Sorscher

**2188** RAF plus EGFR Inhibition for BRAF-Mutant Metastatic Colorectal Cancer—Response  
Rona Yaeger and Leonard B. Saltz

**RETraction**

**2189** Retraction: Glioma-Associated Cancer-Initiating Cells Induce Immunosuppression

**CORRECTIONS**

**2190** Correction: Associations and Interactions between Ets-1 and Ets-2 and Coregulatory Proteins, SRC-1, AIB1, and NCoR in Breast Cancer

**2192** Correction: Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors

### ABOUT THE COVER

The cover shows establishment of blood brain barrier (BBB) tight junctions. Immunofluorescence staining demonstrates ZO-1 expression within the top endothelial layer of an in vitro BBB. For details, see the article by Jilaveanu and colleagues on page 2138 of this issue.
**Clinical Cancer Research**

21 (9)


<table>
<thead>
<tr>
<th>Updated version</th>
<th>Access the most recent version of this article at: <a href="http://clincancerres.aacrjournals.org/content/21/9">http://clincancerres.aacrjournals.org/content/21/9</a></th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th><strong>E-mail alerts</strong></th>
<th>Sign up to receive free email-alerts related to this article or journal.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Reprints and Subscriptions</strong></td>
<td>To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at <a href="mailto:pubs@aacr.org">pubs@aacr.org</a>.</td>
</tr>
<tr>
<td><strong>Permissions</strong></td>
<td>To request permission to re-use all or part of this article, contact the AACR Publications Department at <a href="mailto:permissions@aacr.org">permissions@aacr.org</a>.</td>
</tr>
</tbody>
</table>